MYO - Myomo, Inc.
| Previous Close | 1.7600 |
| Open | 1.7500 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1200 |
| Day's Range | 1.7610 - 1.8173 |
| 52 Week Range | 1.6000 - 5.6300 |
| Volume | 17,722 |
| Avg. Volume | 128,923 |
| Market Cap | 22.246M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8580 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- Business Wire•26 days ago
Myomo Announces First Adolescent Patients to be Fitted with MyoPro
Myomo, Inc., a wearable medical robotics company, has achieved recent momentum fitting and delivering MyoPro to adolescent users. Approved to assist young adults suffering from any disease or injury leaving them with a paralyzed or weakened arm, MyoPro is restoring motion and functionality to adolescents with conditions such as cerebral palsy, brachial plexus injury, and more. MyoPro is now being tested on Acute Flaccid Myelitis ("AFM") patients with promising results.
- GlobeNewswire•last month
Analysis: Positioning to Benefit within Noble Energy, Myomo, Realty Income, Cross Country Healthcare, Ares Management, and Archrock — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•last month
Myomo® Receives Medicare Codes
Myomo, Inc. (NYSE American: MYO) (“Myomo,” or the “Company”), a wearable medical robotics company, announces that the Centers for Medicare & Medicaid Services ("CMS") has published two new codes pursuant to the Company’s application for Healthcare Common Procedure Coding System (HCPCS) “L” codes. Myomo had filed its application in December 2017 to have CMS establish two new Level II HCPCS codes and received a favorable preliminary decision in May.
- Zacks•last month
Myomo, Inc. (MYO) Reports Q3 Loss, Misses Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -5.00% and -25.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire•last month
Myomo Announces Third Quarter 2018 Financial Results
Achieved Revenue Growth of 25% and Reported 222 units in the Reimbursement Process
- Business Wire•last month
Myomo to Report Third Quarter 2018 Results on November 5, 2018
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, today announced that it will release its financial results for the third quarter 2018 on Monday, November 5, 2018, after the US markets close. The Company will host a conference call on Monday, November 5, 2018 at 4:30 p.m. EST featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and Ralph A. Goldwasser, Chief Financial Officer. The conference call, webcast and accompanying slides can be accessed through Myomo’s Investor Relations page.
- Zacks•last month
Myomo, Inc. (MYO) Q3 Earnings Preview: What to Look Out For
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•2 months ago
Are Myomo Inc’s (NYSEMKT:MYO) Interest Costs Too High?
The direct benefit for Myomo Inc (NYSEMKT:MYO), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off is Read More...
- GlobeNewswire•2 months ago
Report: Developing Opportunities within The Ensign Group, Forterra, Inc., Audentes Therapeutics, Assembly Biosciences, Capital Senior Living, and Myomo — Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•2 months ago
Do Institutions Own Shares In Myomo Inc (NYSEMKT:MYO)?
The big shareholder groups in Myomo Inc (NYSEMKT:MYO) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a Read More...
- ACCESSWIRE•3 months ago
Myomo to Present at The MicroCap Conference
/ ACCESSWIRE / September 18, 2018 / Myomo, Inc. (NYSE American: MYO) ("Myomo" or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will be presenting at The MicroCap Conference on Monday, October 1st at 11:00 AM EDT, Track 1, Essex House in New York City. Chairman and Chief Executive Officer Paul R. Gudonis and Chief Financial Officer Ralph A. Goldwasser will be presenting, as well as meeting with investors. A webcast of the presentation will be available at the Investor Relations page of the Company's website.
- IPO Edge•6 months ago
One Year into Reg A+ IPOs, Investment Banker Predicts New Class of Securities to Drive Growth
Mark Elenowitz Says Security Token Offerings May Thrive via Reg A+ We recently sat down for lunch in Manhattan with Mark Elenowitz, CEO of TriPoint Global Equities, to discuss the anniversary of the IPO of Myomo, a wearable medical products company that he took public in the first Reg A+ deal to list on a […]
- Business Wire•3 months ago
Myomo Announces Continued Momentum Across Europe
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, today announced continued momentum across Europe with the appointment of John Frijters as Business Development Manager for EU, a distributor agreement with Bandagist Jan Nielsen to deliver MyoPro to patients across Denmark and the first screening day in the United Kingdom.
- IPO-Edge.com•6 months ago
One Year into Reg A+ IPOs, Investment Banker Predicts New Class of Securities to Drive Growth
Mark Elenowitz Says Security Token Offerings May Thrive via Reg A+ We recently sat down for lunch in Manhattan with Mark Elenowitz, CEO of TriPoint Global Equities, to discuss the anniversary of the IPO of Myomo, a wearable medical products company that he took public in the first Reg A+ deal to list on a […]
- Zacks•4 months ago
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -10.53% and 1.94%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire•4 months ago
Myomo Announces Second Quarter 2018 Financial Results
Achieved Revenue Growth of 106%
- ACCESSWIRE•4 months ago
Myomo, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Myomo, Inc. (NYSE American: MYO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. ...
- Business Wire•4 months ago
Myomo to Report Second Quarter 2018 Results on August 7, 2018
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, today announced that it will release its financial results for the second quarter 2018 on Tuesday, August 7, 2018, after the US markets close. The Company will host a conference call on Tuesday, August 7, 2018 at 4:30 p.m. EDT featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and Ralph A. Goldwasser, Chief Financial Officer. The conference call, webcast and accompanying slides can be accessed through Myomo’s Investor Relations page.
- ACCESSWIRE•5 months ago
Today’s Free Research Reports Coverage on Neovasc and Three More Healthcare Stocks
Under assessment this morning are these four equities: Myomo Inc. (NYSE AMER: MYO), Neovasc Inc. (NASDAQ: NVCN), Smith & Nephew PLC (NYSE: SNN), and Insulet Corp. (NASDAQ: PODD). All you have to do is sign up today for this free limited time offer by clicking the link below.
- Business Wire•5 months ago
Myomo Appoints Micah Mitchell as Chief Commercial Officer
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, announced today that Micah Mitchell is joining the company as chief commercial officer (CCO), a newly created executive role. The addition of a CCO reflects Myomo’s transition from a controlled introduction of its proprietary MyoPro product line to expansion of its sales, marketing, and distribution activities to address the large unmet need of expanded mobility for individuals with arm and hand paralysis.
- Business Wire•5 months ago
Research Team Presents Promising Preliminary Results from TBI Study Using Myomo’s MyoPro
Researchers from the Northwestern University Prosthetics-Orthotics Center (NUPOC) and the Cleveland VA Medical Center have presented promising preliminary case reports from a clinical trial that evaluates the effects of the MyoPro myoelectric arm orthosis (powered brace) from Myomo on traumatic brain injury (TBI) patients at the Cleveland VA Medical Center. The study, which began in 2016 and is funded by the U.S. Department of Defense, includes veterans and non-veterans with TBI who have limited arm or hand functionality. Participants in the study received nine weeks of therapy and training with the MyoPro, followed by nine weeks of home use, with intermittent functional evaluations.
- ACCESSWIRE•6 months ago
Free Pre-Market Technical Recap on MiMedx Group and Three Additional Medical Equipment Stocks
LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on MDXG sign up now at www.wallstequities.com/registration. WallStEquities.com has selected the following stocks for review this morning: Masimo Corp. (NASDAQ: MASI), Medtronic PLC (NYSE: MDT), MiMedx Group Inc. (NASDAQ: MDXG), and Myomo Inc. (NYSE AMER: MYO).
- Simply Wall St.•6 months ago
Top High Growth Stocks This Week
Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitabilityRead More...
- Business Wire•6 months ago
Myomo Brings MyoPro to Adolescent Patients
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, today announced that its MyoPro myoelectric arm orthosis (powered brace) is now available to adolescent patients with paralyzed or weakened arms. MyoPro is the only lightweight wearable device on the market that can help restore substantial functionality in the arms and hands of individuals who are suffering from the effects of a neuromuscular disease or injury. Myomo originally developed MyoPro to assist adults suffering from brachial plexus injury (BPI), brain or spinal cord injury, stroke, multiple sclerosis or ALS.
